- Home
- ILLR vs ALDX Comparison
ILLR vs ALDX Comparison
Compare ILLR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- ALDX
- Stock Information
- Founded
- ILLR 2015
- ALDX 2004
- Country
- ILLR United States
- ALDX United States
- Employees
- ILLR N/A
- ALDX N/A
- Industry
- ILLR Investment Managers
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- ILLR Finance
- ALDX Health Care
- Exchange
- ILLR Nasdaq
- ALDX Nasdaq
- Market Cap
- ILLR 79.7M
- ALDX 342.3M
- IPO Year
- ILLR N/A
- ALDX 2014
- Fundamental
- Price
- ILLR $1.22
- ALDX $5.01
- Analyst Decision
- ILLR
- ALDX Strong Buy
- Analyst Count
- ILLR 0
- ALDX 2
- Target Price
- ILLR N/A
- ALDX $9.50
- AVG Volume (30 Days)
- ILLR 3.6M
- ALDX 809.2K
- Earning Date
- ILLR 11-13-2025
- ALDX 11-06-2025
- Dividend Yield
- ILLR N/A
- ALDX N/A
- EPS Growth
- ILLR N/A
- ALDX N/A
- EPS
- ILLR N/A
- ALDX N/A
- Revenue
- ILLR $45,244,000.00
- ALDX N/A
- Revenue This Year
- ILLR N/A
- ALDX N/A
- Revenue Next Year
- ILLR N/A
- ALDX $63.48
- P/E Ratio
- ILLR N/A
- ALDX N/A
- Revenue Growth
- ILLR N/A
- ALDX N/A
- 52 Week Low
- ILLR $0.40
- ALDX $1.14
- 52 Week High
- ILLR $6.52
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- ILLR 69.54
- ALDX 38.09
- Support Level
- ILLR $0.61
- ALDX $4.88
- Resistance Level
- ILLR $0.76
- ALDX $5.88
- Average True Range (ATR)
- ILLR 0.19
- ALDX 0.29
- MACD
- ILLR 0.09
- ALDX -0.12
- Stochastic Oscillator
- ILLR 61.60
- ALDX 12.38
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.